CMXHY Recent News CNSI Selected by Two Maryland S
Post# of 4
CNSI Selected by Two Maryland State Agencies for Separate IT Development and Support Contracts PR Newswire - Tue Jan 21, 10:00AM CST
New Health Benefits Found in ReishiSmooth(TM) Coffee PR Newswire - Tue Jan 21, 9:47AM CST
iCo Therapeutics Begins Trading on the OTCQX Marketplace PR Newswire - Fri Dec 20, 6:00AM CST
CMS Approves New Technology Add-On Payment for CSL Behring's Kcentra(TM) PR Newswire - Tue Aug 13, 9:37AM CDT
CSL Behring Presents Population Pharmacokinetic Model for Novel Recombinant Factor IX Hemophilia B Treatment That Supports Less Frequent Administration PR Newswire - Wed Jul 03, 10:00AM CDT
CSL Behring Presents Phase I Results From Study of Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers PR Newswire - Wed Jul 03, 10:00AM CDT
CSL Behring International Trial Shows Clinical Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) for Once Weekly Prophylaxis in Patients with Severe Hemophilia B PR Newswire - Wed Jul 03, 7:45AM CDT
CSL Behring Announces Results from Study of Recombinant Single-Chain Factor VIII (rVIII-SingleChain) for Treatment of Hemophilia A PR Newswire - Tue Jul 02, 10:00AM CDT
CSL Behring to Premiere Data from Broad Recombinant Clinical Development Program in Hemophilia at the International Society of Thrombosis and Haemostasis (ISTH) Congress PR Newswire - Thu Jun 27, 8:00AM CDT
CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A PR Newswire - Tue Jun 04, 8:00AM CDT